Your browser is no longer supported. Please, upgrade your browser.
Settings
LOXO Loxo Oncology, Inc. daily Stock Chart
LOXO [NASD]
Loxo Oncology, Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own1.10% Shs Outstand30.61M Perf Week0.05%
Market Cap7.18B Forward P/E- EPS next Y-3.42 Insider Trans-28.36% Shs Float27.32M Perf Month0.42%
Income-63.00M PEG- EPS next Q-0.79 Inst Own99.70% Short Float3.76% Perf Quarter45.33%
Sales144.80M P/S49.61 EPS this Y-53.30% Inst Trans0.45% Short Ratio1.01 Perf Half Y46.97%
Book/sh12.43 P/B18.88 EPS next Y-56.50% ROA-8.70% Target Price225.00 Perf Year132.52%
Cash/sh20.32 P/C11.55 EPS next 5Y37.00% ROE-16.40% 52W Range101.70 - 234.93 Perf YTD67.53%
Dividend- P/FCF31.20 EPS past 5Y- ROI-40.30% 52W High-0.11% Beta2.49
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low130.74% ATR0.47
Employees96 Current Ratio3.60 Sales Q/Q- Oper. Margin-50.30% RSI (14)80.03 Volatility0.11% 0.18%
OptionableYes Debt/Eq0.00 EPS Q/Q63.90% Profit Margin-43.50% Rel Volume0.77 Prev Close234.66
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 BMO Payout- Avg Volume1.02M Price234.66
Recom2.40 SMA200.20% SMA5022.95% SMA20037.64% Volume0 Change0.00%
Nov-15-18Initiated Raymond James Strong Buy $235
Sep-25-18Initiated Leerink Partners Outperform
Sep-17-18Initiated Goldman Neutral $165
Aug-10-18Reiterated Stifel Buy $225 → $217
Jun-04-18Reiterated Stifel Buy $190 → $225
May-17-18Reiterated Stifel Buy $145 → $190
Apr-16-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-22-18Initiated Oppenheimer Outperform $132
Nov-28-17Initiated William Blair Outperform
Aug-29-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-05-17Upgrade Citigroup Neutral → Buy
Jun-05-17Reiterated Stifel Buy $52 → $71
Apr-03-17Initiated Morgan Stanley Overweight $59
Mar-10-17Downgrade Citigroup Buy → Neutral
Feb-08-17Initiated Jefferies Buy $50
Mar-16-16Reiterated Stifel Buy $37 → $36
Jan-15-16Initiated Citigroup Buy $32
Nov-11-15Reiterated Stifel Buy $26 → $37
Sep-02-14Initiated Stifel Buy $20
Feb-15-19 04:10PM  Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company Moody's
11:43AM  Bayer gains full Vitrakvi rights from Eli Lilly's Loxo Reuters
11:33AM  Bayer gains full Vitrakvi rights from Eli Lilly's Loxo Reuters
09:23AM  Lilly Completes Acquisition of Loxo Oncology PR Newswire
Feb-13-19 08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Feb-07-19 07:31AM  5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure Motley Fool
Feb-06-19 04:33PM  Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal TheStreet.com
03:04PM  Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript Motley Fool
11:22AM  Eli Lilly cuts 2019 forecast on trial failure, Loxo deal Reuters
11:19AM  Eli Lilly backs U.S. proposal on drug rebates to lower costs Reuters
09:37AM  Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down Zacks
07:59AM  [$$] Eli Lilly cuts 2019 outlook after trial failure and Loxo deal Financial Times
Feb-05-19 02:03PM  Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript Motley Fool
Feb-04-19 12:12PM  5 of the Best Biotech Stocks to Buy Now InvestorPlace
Feb-03-19 11:34AM  Here's Why Array BioPharma Jumped 31% in January Motley Fool
Feb-01-19 06:45AM  Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction PR Newswire
Jan-28-19 08:46AM  Is the Options Market Predicting a Spike in Loxo Oncology (LOXO) Stock? Zacks
Jan-23-19 10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
Jan-17-19 03:50PM  Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table Investor's Business Daily
07:00AM  Trending: Investors Turn to Dividend Aristocrats Amid Market Volatility ETF Database
Jan-16-19 12:51PM  Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming Investor's Business Daily
Jan-15-19 04:19PM  Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter Investor's Business Daily
04:16PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders GlobeNewswire
Jan-14-19 06:09PM  Eli Lilly CEO Predicts 2019 Will Be Big Year for Biotech Acquisitions GuruFocus.com
08:45AM  Biotech is in the midst of major breakout, but one technician says buyer beware CNBC
Jan-13-19 07:55PM  INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Merger PR Newswire
03:50PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
06:30AM  Here's Why Loxo Oncology Soared 66.4% in 2018, and Another 66% Since Motley Fool
Jan-11-19 04:06PM  Lilly eyes more cancer deals, but wary of CAR-T, gene therapy Reuters
10:31AM  Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference CNBC
09:59AM  The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock InvestorPlace
09:04AM  3 Biotech Stocks Bubbling Away Investopedia
07:46AM  The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference Motley Fool
Jan-10-19 11:00PM  [$$] Financial Times
03:23PM  3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year Motley Fool
Jan-09-19 07:32PM  [$$] Big Pharmas Cancer Race The Wall Street Journal
11:56AM  MERGER ALERT BDMS, LOXO and MB: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
08:25AM  Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now? Motley Fool
Jan-08-19 05:01PM  Why Eli Lilly Is Buying Loxo Oncology for $8 Billion Motley Fool
03:12PM  WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders PR Newswire
09:58AM  Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo Zacks
09:30AM  Company News For Jan 8, 2019 Zacks
08:46AM  Is Eli Lilly Overpaying for Loxo Oncology? Motley Fool
06:26AM  [$$] Stocks to Watch: Amazon, Union Pacific, Lennar, and Loxo Oncology The Wall Street Journal
Jan-07-19 10:48PM  [$$] Eli Lilly to Buy Loxo Oncology in $8 Billion Deal The Wall Street Journal +66.33%
10:14PM  Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy Reuters
07:38PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. (LOXO) on Behalf of Stockholders and Encourages LOXO Investors to Contact the Firm GlobeNewswire
07:01PM  Jim Cramer: These Pharma Deals Are Game Changers TheStreet.com
05:58PM  Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy Reuters
05:12PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Loxo Oncology, Inc. PR Newswire
04:56PM  What Happened in the Stock Market Today Motley Fool
04:53PM  Biotech's big conference living up to reputation with big deals, big costs American City Business Journals
04:26PM  Loxo Oncology, Dollar Tree and Schlumberger rise; PG&E sinks Associated Press
04:24PM  Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference TheStreet.com
04:07PM  Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks TheStreet.com
03:47PM  Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today Motley Fool
03:41PM  LOXO ONCOLOGY, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout Business Wire
03:33PM  [$$] Eli Lilly to Buy Loxo Oncology in $8 Billion Deal The Wall Street Journal
03:06PM  Cancer stocks heat up after third big merger in the past month MarketWatch
03:04PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders GlobeNewswire
02:55PM  Lilly to buy Loxo Oncology in $8 billion cancer push Reuters
01:56PM  Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology ETF Trends
01:56PM  Lilly to buy Loxo Oncology for $8 bln Reuters Videos
01:54PM  Eli Lilly and Company -- Moody's affirms Eli Lilly's A2/P-1 ratings; stable outlook Moody's
12:51PM  Stocks Climb as U.S.-China Trade Talks Begin The Wall Street Journal
12:40PM  Everyone Wants to Be a Biotech Banker Now Bloomberg
12:17PM  Why Agenus Stock Is Spiking Today Motley Fool
12:00PM  WeissLaw LLP Investigates Loxo Oncology Inc. ACCESSWIRE
11:41AM  Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover TheStreet.com
11:11AM  Wall Street Cheers Lilly's $8 Billion Loxo Deal for Cancer Drugs Bloomberg
11:00AM  Here's Why Loxo Oncology Is Skyrocketing Today Motley Fool
10:25AM  Eli Lilly CEO: Loxo acquisition can help us treat cancer ... CNBC Videos
09:53AM  Eli Lilly to Buy Loxo Oncology for $8 Billion Bloomberg
09:40AM  U.S. stocks struggle for direction in early trade, following powerful Friday rally MarketWatch
09:10AM  Eli Lilly confirms $8 billion takeover of Loxo Oncology American City Business Journals
07:49AM  Eli Lilly to spend about $8B on Loxo Oncology Associated Press
07:30AM  [$$] Eli Lilly to buy Loxo Oncology for $8bn in cancer drug push Financial Times
06:50AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology ACCESSWIRE
06:42AM  Eli Lilly to buy cancer treatment company Loxo Oncology for $8 billion in cash Associated Press
06:42AM  Lilly to buy Loxo Oncology in a $8 billion deal, for a 68% premium MarketWatch
06:40AM  Eli Lilly set to buy Loxo Oncology for $8B CNBC Videos
06:34AM  Eli Lilly to acquire Loxo Oncology for about $8 billion CNBC
06:30AM  Lilly Announces Agreement To Acquire Loxo Oncology PR Newswire
Dec-24-18 01:13PM  Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019 Investor's Business Daily
Dec-21-18 06:45AM  Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305 GlobeNewswire
Dec-20-18 01:08PM  DAFNA Capital Management Return, AUM and Holdings Insider Monkey
12:25PM  Did Loxo Oncology, Inc. (NASDAQ:LOXO) Insiders Buy Up More Shares? Simply Wall St.
Dec-10-18 12:24PM  Is Loxo Oncology Inc (LOXO) A Good Stock To Buy? Insider Monkey
Nov-29-18 08:00AM  Recent Analysis Shows Mid-America Apartment Communities, Loxo Oncology, Arista Networks, ADT, Welltower, and First Majestic Silver Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-28-18 08:31AM  5 Things You Need to Know About Loxo Oncology's Revolutionary New Cancer Drug Motley Fool
07:00AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and ACADIA Pharmaceuticals ACCESSWIRE
Nov-27-18 11:14AM  Raymond James Sees $1B Potential In Loxo Oncology's Vitrakvi, LOXO-95 Benzinga -8.91%
08:54AM  Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors Zacks
06:55AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
12:47AM  [$$] Bayer/Loxo: gene machine Financial Times
Nov-26-18 08:32PM  Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod Reuters
07:16PM  FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) GlobeNewswire
05:41PM  Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod Reuters
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Halozyme Therapeutics ACCESSWIRE
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Naider Avi Z.DirectorDec 13Buy138.92725100,716126,843Dec 17 05:07 PM
Bilenker Joshua H.President & CEODec 11Option Exercise13.6710,000136,700174,407Dec 12 05:12 PM
Burstein JenniferSenior VP of FinanceDec 11Option Exercise11.351,25014,1881,250Dec 12 05:14 PM
Van Naarden JacobChief Business OfficerDec 11Option Exercise7.5711,50087,05120,700Dec 12 05:17 PM
Bilenker Joshua H.President & CEODec 11Sale137.4210,0001,374,237164,407Dec 12 05:12 PM
Burstein JenniferSenior VP of FinanceDec 11Sale137.431,250171,7920Dec 12 05:14 PM
Van Naarden JacobChief Business OfficerDec 11Sale137.354,500618,08013,700Dec 12 05:17 PM
Bilenker Joshua H.President & CEODec 10Option Exercise13.6710,000136,700174,407Dec 12 05:12 PM
Burstein JenniferSenior VP of FinanceDec 10Option Exercise11.351,25014,1881,250Dec 12 05:14 PM
Van Naarden JacobChief Business OfficerDec 10Option Exercise13.674,50061,51518,200Dec 12 05:17 PM
Bilenker Joshua H.President & CEODec 10Sale133.5210,0001,335,198164,407Dec 12 05:12 PM
Burstein JenniferSenior VP of FinanceDec 10Sale133.671,250167,0840Dec 12 05:14 PM
Van Naarden JacobChief Business OfficerDec 10Sale133.654,500601,43413,700Dec 12 05:17 PM
Bilenker Joshua H.President & CEONov 27Option Exercise13.6710,000136,700174,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 27Option Exercise11.351,25014,1881,250Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 27Option Exercise8.234,50037,03118,200Nov 28 05:13 PM
Bilenker Joshua H.President & CEONov 27Sale141.3410,0001,413,418164,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 27Sale142.281,250177,8510Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 27Sale141.664,500637,48113,700Nov 28 05:13 PM
Bilenker Joshua H.President & CEONov 26Option Exercise2.2039,00085,709174,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 26Option Exercise11.351,25014,1881,250Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 26Option Exercise3.655,50020,06419,200Nov 28 05:13 PM
Bilenker Joshua H.President & CEONov 26Sale153.1810,0001,531,829164,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 26Sale153.081,250191,3560Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 26Sale153.135,500842,22413,700Nov 28 05:13 PM
Bilenker Joshua H.President & CEOOct 04Option Exercise3.6510,00036,480145,407Oct 05 04:42 PM
Burstein JenniferSenior VP of FinanceOct 04Option Exercise11.351,25014,1881,250Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 04Option Exercise3.654,50016,41618,200Oct 05 04:46 PM
Burstein JenniferSenior VP of FinanceOct 04Sale162.641,250203,3040Oct 05 04:44 PM
Bilenker Joshua H.President & CEOOct 04Sale162.6210,0001,626,246135,407Oct 05 04:42 PM
Van Naarden JacobChief Business OfficerOct 04Sale162.644,500731,88413,700Oct 05 04:46 PM
Burstein JenniferSenior VP of FinanceOct 03Option Exercise11.351,25014,1881,250Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 03Option Exercise3.655,50020,06419,200Oct 05 04:46 PM
Van Naarden JacobChief Business OfficerOct 03Sale167.165,500919,37813,700Oct 05 04:46 PM
Burstein JenniferSenior VP of FinanceOct 03Sale167.201,250208,9960Oct 05 04:44 PM
Bilenker Joshua H.President & CEOOct 03Sale168.187,0951,193,254135,407Oct 05 04:42 PM
Kunkel Lori AnneDirectorOct 01Option Exercise3.655,00018,2405,000Oct 03 05:05 PM
Kunkel Lori AnneDirectorOct 01Sale170.375,000851,8290Oct 03 05:05 PM
Van Naarden JacobChief Business OfficerSep 13Option Exercise3.654,50016,41618,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 13Option Exercise1.8110,00018,067145,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 13Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Burstein JenniferSenior VP of FinanceSep 13Sale166.021,250207,5230Sep 14 06:19 PM
Bilenker Joshua H.President & CEOSep 13Sale165.9810,0001,659,805135,407Sep 14 06:17 PM
Van Naarden JacobChief Business OfficerSep 13Sale165.984,500746,90313,700Sep 14 06:14 PM
Van Naarden JacobChief Business OfficerSep 12Option Exercise3.655,50020,06419,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 12Option Exercise1.1810,00011,840145,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 12Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Burstein JenniferSenior VP of FinanceSep 12Sale167.891,250209,8690Sep 14 06:19 PM
Bilenker Joshua H.President & CEOSep 12Sale166.4210,0001,664,159135,407Sep 14 06:17 PM
Van Naarden JacobChief Business OfficerSep 12Sale166.605,500916,27613,700Sep 14 06:14 PM
Bilenker Joshua H.President & CEOAug 14Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 14Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 14Option Exercise3.654,50016,41618,200Aug 15 05:27 PM
Van Naarden JacobChief Business OfficerAug 14Sale159.924,500719,64213,700Aug 15 05:27 PM
Burstein JenniferSenior VP of FinanceAug 14Sale160.221,250200,2790Aug 15 05:25 PM
Bilenker Joshua H.President & CEOAug 14Sale159.9110,0001,599,089135,407Aug 15 05:23 PM
Bilenker Joshua H.President & CEOAug 13Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 13Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 13Option Exercise3.655,50020,06419,200Aug 15 05:27 PM
Van Naarden JacobChief Business OfficerAug 13Sale158.875,500873,80413,700Aug 15 05:27 PM
Burstein JenniferSenior VP of FinanceAug 13Sale158.261,250197,8270Aug 15 05:25 PM
Bilenker Joshua H.President & CEOAug 13Sale158.9110,0001,589,092135,407Aug 15 05:23 PM
Bilenker Joshua H.President & CEOJul 10Option Exercise1.187,5008,880142,907Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 10Option Exercise3.651,5415,62215,241Jul 11 05:03 PM
AISLING CAPITAL III LP10% OwnerJul 10Sale179.431,400,000251,202,0002,038,920Jul 12 04:45 PM
Van Naarden JacobChief Business OfficerJul 10Sale179.691,541276,90713,700Jul 11 05:03 PM
Bilenker Joshua H.President & CEOJul 10Sale179.727,5001,347,923135,407Jul 11 05:01 PM
Bilenker Joshua H.President & CEOJul 09Option Exercise1.187,5008,880142,907Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 09Option Exercise3.651,5415,62215,241Jul 11 05:03 PM
Burstein JenniferSenior VP of FinanceJul 09Option Exercise11.351,50017,0251,500Jul 11 05:04 PM
Burstein JenniferSenior VP of FinanceJul 09Sale187.251,500280,8700Jul 11 05:04 PM
Van Naarden JacobChief Business OfficerJul 09Sale187.301,541288,63113,700Jul 11 05:03 PM
Bilenker Joshua H.President & CEOJul 09Sale187.237,5001,404,241135,407Jul 11 05:01 PM
Bilenker Joshua H.President & CEOJun 20Option Exercise1.1835,50042,032163,207Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 20Option Exercise3.6513,54149,39813,541Jun 21 05:03 PM
Van Naarden JacobChief Business OfficerJun 20Sale179.341,541276,37012,000Jun 21 05:03 PM
Bilenker Joshua H.President & CEOJun 20Sale179.3321,0003,765,8328,000Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 20Sale179.257,5001,344,405155,707Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 19Option Exercise1.187,5008,880135,207Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 19Option Exercise3.651,5415,6221,541Jun 21 05:03 PM
Burstein JenniferSenior VP of FinanceJun 19Option Exercise11.351,70019,2951,700Jun 21 05:04 PM
Burstein JenniferSenior VP of FinanceJun 19Sale176.991,700300,8880Jun 21 05:04 PM
Van Naarden JacobChief Business OfficerJun 19Sale176.941,541272,6660Jun 21 05:03 PM
Bilenker Joshua H.President & CEOJun 19Sale178.2521,0003,743,35329,000Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 19Sale177.047,5001,327,766127,707Jun 21 05:02 PM
Kunkel Lori AnneDirectorJun 15Sale176.866,8401,209,6890Jun 18 05:00 PM
Kunkel Lori AnneDirectorJun 14Option Exercise6.5432,392211,70839,232Jun 18 05:00 PM
Kunkel Lori AnneDirectorJun 14Sale180.4632,3925,845,5646,840Jun 18 05:00 PM
Fuhrman AlanDirectorJun 08Option Exercise11.352,62529,7942,625Jun 11 06:01 PM
MAYLEBEN TIMOTHY MDirectorJun 08Option Exercise21.7510,000217,55010,000Jun 11 06:02 PM
MAYLEBEN TIMOTHY MDirectorJun 08Sale179.5510,0001,795,4690Jun 11 06:02 PM
Fuhrman AlanDirectorJun 08Sale178.072,625467,4370Jun 11 06:01 PM
Flaherty Keith T.DirectorJun 07Option Exercise1.1850,00059,20059,732Jun 11 06:00 PM
Flaherty Keith T.DirectorJun 07Sale173.5450,0008,677,0279,732Jun 11 06:00 PM
Bilenker Joshua H.President & CEOMay 15Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 15Option Exercise3.651,5415,6221,541May 16 04:46 PM
Van Naarden JacobChief Business OfficerMay 15Sale137.291,541211,5660May 16 04:46 PM
Bilenker Joshua H.President & CEOMay 15Sale137.417,5001,030,575182,707May 16 04:44 PM
Bilenker Joshua H.President & CEOMay 14Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 14Option Exercise3.651,5415,6221,541May 16 04:46 PM